CORRECTION: Axsome Therapeutics Q4 Adjusted EPS $(0.73) Beats $(1.15) Estimate, Sales $71.53M Beat $67.69M Estimate
Portfolio Pulse from Benzinga Newsdesk
Axsome Therapeutics (NASDAQ:AXSM) reported Q4 adjusted EPS of $(0.73), surpassing the $(1.15) estimate, and sales of $71.53M, exceeding the $67.69M estimate. This represents a significant improvement over the previous year, with a 48.23% decrease in losses per share and a 193.50% increase in sales.
February 21, 2024 | 12:03 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Axsome Therapeutics reported a significant beat on both EPS and sales estimates for Q4, showing substantial year-over-year growth.
Beating both EPS and sales estimates significantly, especially with such a large year-over-year growth in sales (193.50%) and a notable reduction in losses per share (48.23%), is likely to be viewed positively by investors. This performance indicates strong operational progress and could lead to increased investor confidence and demand for AXSM shares, potentially driving the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100